SPDR S&P Biotech ETF $XBI Stock Sold by Parkside Investments LLC

Parkside Investments LLC reduced its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 4.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,303 shares of the exchange traded fund’s stock after selling 3,420 shares during the period. SPDR S&P Biotech ETF accounts for approximately 1.5% of Parkside Investments LLC’s investment portfolio, making the stock its 17th biggest position. Parkside Investments LLC’s holdings in SPDR S&P Biotech ETF were worth $12,978,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of XBI. Bank of America Corp DE raised its position in shares of SPDR S&P Biotech ETF by 13.3% in the first quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock valued at $1,854,388,000 after purchasing an additional 1,700,851 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of SPDR S&P Biotech ETF by 7.8% during the 4th quarter. Hsbc Holdings PLC now owns 638,529 shares of the exchange traded fund’s stock worth $78,049,000 after buying an additional 46,339 shares during the period. Main Street Research LLC grew its stake in SPDR S&P Biotech ETF by 57.4% in the 1st quarter. Main Street Research LLC now owns 567,479 shares of the exchange traded fund’s stock valued at $72,484,000 after buying an additional 206,953 shares during the last quarter. Strs Ohio grew its stake in SPDR S&P Biotech ETF by 4.9% in the 1st quarter. Strs Ohio now owns 410,500 shares of the exchange traded fund’s stock valued at $52,433,000 after buying an additional 19,300 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in SPDR S&P Biotech ETF by 41.4% in the 1st quarter. SG Americas Securities LLC now owns 391,243 shares of the exchange traded fund’s stock valued at $49,973,000 after buying an additional 114,638 shares during the last quarter.

SPDR S&P Biotech ETF Stock Up 3.6%

SPDR S&P Biotech ETF stock opened at $153.24 on Wednesday. The stock has a market cap of $10.58 billion, a P/E ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a twelve month low of $106.30 and a twelve month high of $169.89. The company’s 50-day moving average price is $157.79 and its two-hundred day moving average price is $147.39.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.